Saturday, October 29, 2011

Cannabinoid 'Completely' Prevents Chemotherapy-Induced Neuropathy, Study Says

link

Wednesday, 19 October 2011

Philadelphia, PA: The administration of the non-psychotropic plant cannabinoid cannabidiol (CBD) 'completely prevents' the onset of nerve pain associated with chemotherapy treatment, according to preclinical data published in the journal Anesthesia and Analgesia.

Investigators at Temple University assessed the effect of CBD in an animal model of on paclitaxel-induced allodynia (pain resulting from an otherwise innocuous stimulus).

"We found that cannabidiol completely prevented the onset of the neuropathic, or nerve pain caused by the chemo drug Paclitaxel, which is used to treat breast cancer," said the study's lead investigator.

Researchers concluded, "Our preliminary findings therefore indicate that cannabidiol may ... therefore be effective at preventing dose-limiting paclitaxel-induced peripheral neuropathy in humans.

Cannabidiol has been previously shown to inhibit breast cancer metastasis in preclinical settings.

In 2010, a series of FDA-approved clinical trials concluded that inhaled cannabis significantly reduces neuropathy compared to placebo in human subjects. "There is good evidence now that cannabinoids may be either an adjunct or a first-line treatment for ... neuropathy," researchers concluded.

For more information, please contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, "Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice," appears in the October edition of journal Anesthesia and Analgesia.

Saturday, October 15, 2011

Mayo Clinic Finds Massive Fraud In Cancer Research

Original Link

New Discovery Shakes the Foundation of Cancer Research

Posted By Dr. Mercola | October 15 2011 | 33,082 views

cancer research fraud
Story at-a-glance
  • Two widely cited, published cancer research studies contain fabricated data, will be retracted
  • The Mayo Clinic concluded that data about harnessing the immune system to fight cancer had been fabricated, resulting in the retraction of 17 papers in nine research journals
  • Cancer research in the United States needs to be scrutinized, as much is money-driven and based on developing new drugs

By Dr. Mercola

In a scandal that has reverberated around the world of cancer research, the Office of Research Integrity at the U.S. Department of Health found that a Boston University cancer scientist fabricated his findings. His work was published in two journals in 2009, and he’s been ordered to retract them. But important studies by other scientists like those at the Mayo Clinic, who based their work on his findings, could now make 10 years of their studies worthless, according to commentary in Gaia Health.

It seems fairly evident that the cancer industrial complex is a highly lucrative, well-oiled system that tends to support funding for expensive drug treatments that don't address the cause of the problem, and have yet to make a significant dent in the decrease of the overall cancer rate in the US despite investing hundreds of billions of dollars. Much of the support comes from flawed and biased "research" studies that support the use of expensive drugs as detailed in the featured articles.

Researchers, too, are well aware of the notoriety and money to be found in cancer research … particularly what may be deemed successful cancer research (which unfortunately is often measured by the discovery of new drug treatments). But, as with many areas of medical research, it's important to read between the lines of "scientifically proven" studies, even those that are well accepted.

Often what you'll find is the research gives the perception of science when really it is a heavily manipulated process designed to control and deceive. Case in point, here again we have an example of widely accepted, published research that turned out to be fabricated.

10 Years of Cancer Research Down the Drain

The Office of Research Integrity (ORI) at the U.S. Department of Health reported in August 2011 that final action has been taken against Sheng Wang, PhD, of Boston University School of Medicine, Cancer Research Center. ORI states:

"The Respondent engaged in research misconduct by fabricating data that were included in two (2) published papers."

This includes:

  • Oncogene February 2009, which found that HIC1, a protein thought to suppress tumor growth, is a "central molecule in a novel mechanism controlling cell growth and that the disruption of this HIC1-mediated pathway may lead to abnormal cell proliferation and, ultimately, cancer."
  • Molecular Endocrinology December 2009, which found "reintroducing HIC1 into resistant breast cancer cells restored their sensitivity to the estrogen antagonists, indicating the existence of a novel regulatory mechanism for growth control of breast cancer cells."

Specifically, six of the eight figures in the Oncogene paper and six of the seven figures in the Molecular Endocrinology study were said to contain data from fabricated experiments. Though Wang is now required to retract the papers, and he reportedly stopped working for Boston University in July, he will only be ineligible for federal funding for 2 years.

Further, the fabricated research may continue to live on, as it has been cited by other studies and once a finding is accepted in the medical community, it's very hard to make it go away. Unfortunately, scientific retractions are actually becoming increasingly common.

As the Wall Street Journal reported:

"Just 22 retraction notices appeared in 2001, but 139 in 2006 and 339 last year. Through seven months of this year, there have been 210, according to Thomson Reuters Web of Science, an index of 11,600 peer-reviewed journals world-wide …

At the Mayo Clinic, a decade of cancer research, partly taxpayer-funded, went down the drain when the prestigious Minnesota institution concluded that intriguing data about harnessing the immune system to fight cancer had been fabricated. Seventeen scholarly papers published in nine research journals had to be retracted. A researcher, who protests his innocence, was fired. In another major flameout, 18 research journals have said they are planning to retract a total of 89 published studies by a German anesthesiologist …"



read more at here...